GLYC Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of -- compared to GlycoMimetics's net margin of 14.23%. GlycoMimetics's return on equity of -- beat Biomarin Pharmaceutical's return on equity of 6.29%.

GlycoMimetics has a consensus price target of --, signalling upside risk potential of 327.9%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.08 which suggests that it could grow by 49.31%. Given that GlycoMimetics has higher upside potential than Biomarin Pharmaceutical, analysts believe GlycoMimetics is more attractive than Biomarin Pharmaceutical.

GlycoMimetics has a beta of 1.771, which suggesting that the stock is 77.069% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.295, suggesting its less volatile than the S&P 500 by 70.544%.

GlycoMimetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlycoMimetics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

GlycoMimetics quarterly revenues are --, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. GlycoMimetics's net income of -$9.8M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, GlycoMimetics's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 39.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlycoMimetics is -- versus 4.69x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Cidara Therapeutics has a net margin of -- compared to GlycoMimetics's net margin of -30201.66%. GlycoMimetics's return on equity of -- beat Cidara Therapeutics's return on equity of -443.37%.

GlycoMimetics has a consensus price target of --, signalling upside risk potential of 327.9%. On the other hand Cidara Therapeutics has an analysts' consensus of -- which suggests that it could grow by 24.89%. Given that GlycoMimetics has higher upside potential than Cidara Therapeutics, analysts believe GlycoMimetics is more attractive than Cidara Therapeutics.

GlycoMimetics has a beta of 1.771, which suggesting that the stock is 77.069% more volatile than S&P 500. In comparison Cidara Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.883%.

GlycoMimetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlycoMimetics pays -- of its earnings as a dividend. Cidara Therapeutics pays out -- of its earnings as a dividend.

GlycoMimetics quarterly revenues are --, which are smaller than Cidara Therapeutics quarterly revenues of $302K. GlycoMimetics's net income of -$9.8M is higher than Cidara Therapeutics's net income of -$16M. Notably, GlycoMimetics's price-to-earnings ratio is -- while Cidara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlycoMimetics is -- versus 1.91x for Cidara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

FibroGen has a net margin of -- compared to GlycoMimetics's net margin of -36.87%. GlycoMimetics's return on equity of -- beat FibroGen's return on equity of --.

GlycoMimetics has a consensus price target of --, signalling upside risk potential of 327.9%. On the other hand FibroGen has an analysts' consensus of $10.00 which suggests that it could grow by 2400%. Given that FibroGen has higher upside potential than GlycoMimetics, analysts believe FibroGen is more attractive than GlycoMimetics.

GlycoMimetics has a beta of 1.771, which suggesting that the stock is 77.069% more volatile than S&P 500. In comparison FibroGen has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.658%.

GlycoMimetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FibroGen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlycoMimetics pays -- of its earnings as a dividend. FibroGen pays out -- of its earnings as a dividend.

GlycoMimetics quarterly revenues are --, which are smaller than FibroGen quarterly revenues of $46.3M. GlycoMimetics's net income of -$9.8M is higher than FibroGen's net income of -$17.1M. Notably, GlycoMimetics's price-to-earnings ratio is -- while FibroGen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlycoMimetics is -- versus 0.22x for FibroGen. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -- compared to GlycoMimetics's net margin of -63.65%. GlycoMimetics's return on equity of -- beat Revance Therapeutics's return on equity of --.

GlycoMimetics has a consensus price target of --, signalling upside risk potential of 327.9%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 147.96%. Given that GlycoMimetics has higher upside potential than Revance Therapeutics, analysts believe GlycoMimetics is more attractive than Revance Therapeutics.

GlycoMimetics has a beta of 1.771, which suggesting that the stock is 77.069% more volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.478%.

GlycoMimetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlycoMimetics pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

GlycoMimetics quarterly revenues are --, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. GlycoMimetics's net income of -$9.8M is higher than Revance Therapeutics's net income of -$38.1M. Notably, GlycoMimetics's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlycoMimetics is -- versus 1.16x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.